| __timestamp | BioCryst Pharmaceuticals, Inc. | Grifols, S.A. |
|---|---|---|
| Wednesday, January 1, 2014 | 7461000 | 660772000 |
| Thursday, January 1, 2015 | 13047000 | 736435000 |
| Friday, January 1, 2016 | 11253000 | 775266000 |
| Sunday, January 1, 2017 | 13933000 | 860348000 |
| Monday, January 1, 2018 | 29514000 | 814775000 |
| Tuesday, January 1, 2019 | 37121000 | 942821000 |
| Wednesday, January 1, 2020 | 67929000 | 985616000 |
| Friday, January 1, 2021 | 118818000 | 1061508000 |
| Saturday, January 1, 2022 | 159371000 | 1190423000 |
| Sunday, January 1, 2023 | 213894000 | 1254234000 |
Unleashing insights
In the ever-evolving pharmaceutical landscape, effective cost management is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Grifols, S.A. and BioCryst Pharmaceuticals, Inc. over the past decade. From 2014 to 2023, Grifols, S.A. consistently outpaced BioCryst in SG&A spending, with expenses peaking at approximately €1.25 billion in 2023, marking a 90% increase from 2014. In contrast, BioCryst's SG&A expenses surged by nearly 280%, reaching around €214 million in 2023. This stark difference highlights Grifols' established market presence and BioCryst's rapid growth trajectory. Understanding these trends offers valuable insights into each company's strategic priorities and operational efficiencies. As the pharmaceutical industry continues to expand, monitoring SG&A expenses remains a key indicator of financial health and competitive positioning.
Comparing SG&A Expenses: AbbVie Inc. vs Grifols, S.A. Trends and Insights
Selling, General, and Administrative Costs: Bristol-Myers Squibb Company vs Grifols, S.A.
Breaking Down SG&A Expenses: Gilead Sciences, Inc. vs BioCryst Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Neurocrine Biosciences, Inc. and BioCryst Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Insmed Incorporated or BioCryst Pharmaceuticals, Inc.
BioMarin Pharmaceutical Inc. vs Grifols, S.A.: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Halozyme Therapeutics, Inc. and Grifols, S.A.
Breaking Down SG&A Expenses: Grifols, S.A. vs TG Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Grifols, S.A. or Iovance Biotherapeutics, Inc.
Cost of Revenue Trends: Grifols, S.A. vs BioCryst Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing ADMA Biologics, Inc. and BioCryst Pharmaceuticals, Inc.
Mesoblast Limited and BioCryst Pharmaceuticals, Inc.: SG&A Spending Patterns Compared